These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 9463684)

  • 41. Long-term immunity and immune response to a booster dose following vaccination with the inactivated Japanese encephalitis vaccine IXIARO, IC51.
    Dubischar-Kastner K; Eder S; Buerger V; Gartner-Woelfl G; Kaltenboeck A; Schuller E; Tauber E; Klade C
    Vaccine; 2010 Jul; 28(32):5197-202. PubMed ID: 20541581
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dengue plaque reduction neutralization test (PRNT) in primary and secondary dengue virus infections: How alterations in assay conditions impact performance.
    Thomas SJ; Nisalak A; Anderson KB; Libraty DH; Kalayanarooj S; Vaughn DW; Putnak R; Gibbons RV; Jarman R; Endy TP
    Am J Trop Med Hyg; 2009 Nov; 81(5):825-33. PubMed ID: 19861618
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Induction of neutralizing antibodies against dengue virus type 2 upon mucosal administration of a recombinant Lactococcus lactis strain expressing envelope domain III antigen.
    Sim AC; Lin W; Tan GK; Sim MS; Chow VT; Alonso S
    Vaccine; 2008 Feb; 26(9):1145-54. PubMed ID: 18243432
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evaluation of chimeric DNA vaccines consisting of premembrane and envelope genes of Japanese encephalitis and dengue viruses as a strategy for reducing induction of dengue virus infection-enhancing antibody response.
    Sjatha F; Kuwahara M; Sudiro TM; Kameoka M; Konishi E
    Microbiol Immunol; 2014 Feb; 58(2):126-34. PubMed ID: 24372832
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Changes in dengue and Japanese encephalitis (JE) antibody after JE vaccination.
    Quina MA; Thein S; Auvanich W; Okuno Y; Igarashi A; Fukai K
    Biken J; 1978 Dec; 21(4):149-59. PubMed ID: 754688
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Investigation of dengue and Japanese encephalitis virus transmission in Hanam, Viet Nam.
    Fox A; Whitehead S; Anders KL; Hoa LNM; Mai LQ; Thai PQ; Yen NT; Duong TN; Thoang DD; Farrar J; Wertheim H; Simmons C; Hien NT; Horby P
    Am J Trop Med Hyg; 2014 May; 90(5):892-896. PubMed ID: 24615123
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Standardization of serum neutralization assay of Japanese encephalitis virus (Nakayama NIH strain) on BHK-21 (Cl-13) cell line.
    Singh S; Sharma M; Kumar S; Gowal D
    Acta Virol; 2015 Sep; 59(3):234-9. PubMed ID: 26435146
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immunogenicity and safety of a tetravalent dengue vaccine in healthy adults in India: A randomized, observer-blind, placebo-controlled phase II trial.
    Dubey AP; Agarkhedkar S; Chhatwal J; Narayan A; Ganguly S; Wartel TA; Bouckenooghe A; Menezes J
    Hum Vaccin Immunother; 2016; 12(2):512-8. PubMed ID: 26291554
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Seroepidemiology study of Japanese encephalitis neutralizing antibodies in southern Taiwan: a comparative study between urban city and country townships.
    Tseng HF; Tan HF; Chang CK; Huang WL; Ho WC
    Am J Infect Control; 2003 Nov; 31(7):435-40. PubMed ID: 14639442
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Nonstructural protein 1 antibody-based epitope-blocking enzyme-linked immunosorbent assay to differentiate Japanese encephalitis virus from dengue virus infections in humans.
    Konishi E; Konishi M
    Jpn J Infect Dis; 2011; 64(4):284-91. PubMed ID: 21788702
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A randomized study of the immunogenicity and safety of Japanese encephalitis chimeric virus vaccine (JE-CV) in comparison with SA14-14-2 vaccine in children in the Republic of Korea.
    Kim DS; Houillon G; Jang GC; Cha SH; Choi SH; Lee J; Kim HM; Kim JH; Kang JH; Kim JH; Kim KH; Kim HS; Bang J; Naimi Z; Bosch-Castells V; Boaz M; Bouckenooghe A
    Hum Vaccin Immunother; 2014; 10(9):2656-63. PubMed ID: 25483480
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of Neutralizing Antibody Titers against Japanese Encephalitis Virus Genotype V Strain with Those against Genotype I and III Strains in the Sera of Japanese Encephalitis Patients in Japan in 2016.
    Maeki T; Tajima S; Kyaw AK; Matsumoto F; Miura K; Yamashita A; Yoshikawa A; Negishi K; Noguchi Y; Tadokoro K; Abe K; Taruya J; Koh J; Ito H; Ikegaya A; Abe F; Wada M; Nishigata T; Ikeda M; Kato F; Taniguchi S; Nakayama E; Takasaki T; Morita K; Lim CK; Saijo M
    Jpn J Infect Dis; 2018 Sep; 71(5):360-364. PubMed ID: 29962489
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Accuracy and repeatability of a micro plaque reduction neutralization test for vaccinia antibodies.
    Borges MB; Kato SE; Damaso CR; Moussatché N; da Silva Freire M; Lambert Passos SR; do Nascimento JP
    Biologicals; 2008 Mar; 36(2):105-10. PubMed ID: 17892944
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A simple assay system for infection-enhancing and -neutralizing antibodies to dengue type 2 virus using layers of semi-adherent K562 cells.
    Konishi E; Tabuchi Y; Yamanaka A
    J Virol Methods; 2010 Feb; 163(2):360-7. PubMed ID: 19883692
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immunogenicity of a Japanese encephalitis chimeric virus vaccine as a booster dose after primary vaccination with SA14-14-2 vaccine in Thai children.
    Janewongwirot P; Puthanakit T; Anugulruengkitt S; Jantarabenjakul W; Phasomsap C; Chumket S; Yoksan S; Pancharoen C
    Vaccine; 2016 Oct; 34(44):5279-5283. PubMed ID: 27628323
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immunogenicity of live attenuated Japanese encephalitis SA 14-14-2 vaccine among Sri Lankan children with previous receipt of inactivated JE vaccine.
    Wijesinghe PR; Abeysinghe MRN; Yoksan S; Yao Y; Zhou B; Zhang L; Fleming JA; Marfin AA; Victor JC
    Vaccine; 2016 Nov; 34(48):5923-5928. PubMed ID: 27773472
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Japanese encephalitis DNA vaccine candidates expressing premembrane and envelope genes induce virus-specific memory B cells and long-lasting antibodies in swine.
    Konishi E; Yamaoka M; Kurane I; Mason PW
    Virology; 2000 Mar; 268(1):49-55. PubMed ID: 10683326
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Variability in dengue titer estimates from plaque reduction neutralization tests poses a challenge to epidemiological studies and vaccine development.
    Salje H; Rodríguez-Barraquer I; Rainwater-Lovett K; Nisalak A; Thaisomboonsuk B; Thomas SJ; Fernandez S; Jarman RG; Yoon IK; Cummings DA
    PLoS Negl Trop Dis; 2014 Jun; 8(6):e2952. PubMed ID: 24967885
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Zika Virus-Induced Antibody Response Enhances Dengue Virus Serotype 2 Replication In Vitro.
    Kawiecki AB; Christofferson RC
    J Infect Dis; 2016 Nov; 214(9):1357-1360. PubMed ID: 27521359
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Humoral immunity and correlation between ELISA, hemagglutination inhibition, and neutralization tests after vaccination against tick-borne encephalitis virus in children.
    Venturi G; Mel R; Marchi A; Mancuso S; Russino F; Pra GD; Papa N; Bertiato G; Fiorentini C; Ciufolini MG
    J Virol Methods; 2006 Jun; 134(1-2):136-9. PubMed ID: 16458368
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.